Background: PTEN and TP53 are among the most frequently mutated tumor suppressor genes in human glioblastoma which is the most common and most aggressive primary brain tumor. Both pathways are concurrently dysregulated in greater than 90% of glioblastoma. How loss of PTEN and TP53 contribute to the gliomagenesis and the role of PTEN function in both developmental and oncogenic contexts need be further characterized. Background: A blind painful eye (BPE) is the end stage clinical diagnosis of several ocular diseases, including inflammatory, vascular, and glaucomatous conditions. The morphological findings that can be encountered are broad and often related to the original condition. The aim of this study is to document the frequency of the most common morphological features in BPE by topographical location. Design: In total, 167 cases clinically diagnosed with BPE over a 21-year period were reviewed. The cases were categorized as enucleations (54.5%) and eviscerations (44.5%). The morphological findings were subdivided accordingly to each topographic intraocular location. Results: Mean age at diagnosis was 55.6 years (1-88) with equal sex distribution. In enucleation and evisceration specimens, the two most common findings in each topographic location were as follows (respectively): in the cornea, chronic keratitis with neovascularization (78%/85.3%) and subepithelial pannus (22%/30.7%); in the iris, anterior synechia (35.2%/17%) and rubeosis iridis (12,1/not applicable [NA]); in the trabecular meshwork, angle closure glaucoma (44%/NA); in the anterior chamber, epithelial ingrowth (3.3%/NA); in the lens, cataract (20.9%/24%); in the retina, retinal detachment (67%/NA) and retinal gliosis (64.8%/77.3%); in the choroid, nongranulomatous uveitis (44%/66.7%); and for optic nerve, optic nerve atrophy (45%/ NA). Important diagnoses included two cases consistent with sympathetic ophthalmia, two Fuch's adenomas, and one toxoplasmosis case. Phthisical eyes were diagnosed by osseous metaplasia or shrunken eyes (<16 mm in diameter) and represented 23.9% of all enucleations. Conclusions: To the best of our knowledge, this is the first topographic study of blind painful eyes describing the histopathological features. Pathological evaluation of blind painful eyes is mainly used to rule out symphathetic ophthalmia, neoplasias, and infections, but there are also other subtle findings that may be useful to confirm the underlying clinical condition. Pablo Zoroquiain, Sultan Aldrees, Mohammed Qutub, Patrick Logan, Leonardo Dias, Miguel N Burnier. Mcgill University, Montreal, QC, Canada. Background: Primary carcinomas with apocrine differentiation (CAD) are infrequent tumors with several subtypes, including apocrine adenocarcinomas (AAs), extramammary Paget's disease, adenoid cystic carcinoma, and mucinous carcinoma (MC) among others. The purpose of this study is to describe the clinical and pathological characteristics of CAD in order to assist with differential diagnoses. Design: We reviewed 5,453 cases diagnosed at the Henry C. Witelson Ocular Pathology Laboratory, Montreal, Quebec over an 8-year period. Clinical and pathological data of all CAD diagnosed during this period were retrieved. Descriptive analysis, including frequency, size, location, gender, and age, was performed. Results: Of the 5,453 specimens reviewed, 3,014 (55.3%) cases were eyelid lesions. Five CAD cases were identified. Two cases were AAs and three cases MC (0.07% and 0.17% of the eyelid lesions, respectively). The AAs were diagnosed in a 59-year-old male and an 81-year-old female in the lower and upper eyelid, respectively. Both were clinically diagnosed as chalazions. Average lesion size was 4 mm and both cases showed luminal border decapitation and eosinophilic cytoplasm. One carcinoma was well demarcated with high pleomorphism, while the other showed infiltrative borders and bland cytological features. After 2 and 3 years of follow-up, respectively, no recurrences were seen. The MCs were diagnosed in three males (61, 88, and 84 years) with an average size of 10 mm. Two of them occurred in the lower eyelid. They were all clinically diagnosed as cystic basal cell carcinoma. All of them were characterized by mucin pools separated by thin fibrous septa with nests of cribiform cells. In one case, an intraepithelial component was seen favoring the primary nature of the lesion. One patient experienced local recurrence after 6 years of follow-up. Conclusions: To the best of our knowledge, this is the first comprehensive review of CAD of the eylid from a single institution. CAD are exceedingly rare low-grade malignant tumors with the potential for recurrence. The morphological spectrum of CAD is broad. Chalazion was the clinical misdiagnosis in all AAs, while MCs were misdiagnosed as cystic basal cell carcinomas. Identifying the intraepithelial portion of MCs may aid in the differential diagnosis of metastatic tumors. We encourage surgeons to submit all chalazions for pathological diagnosis due to the possibility that they may be malignant lesions.
Molecular Profile of Pancreas Ductal Adenocarcinoma with CancerSCANTM Panel Analysis
Misun Choi, Kee-Taek Jang, Donghyun Park, Woongyang Park, Seoung Ho Choi. Samsung Medical Center, Seoul, Republic of Korea; Sungkyunkwan University School of Medicine, Suwon, Gyeonggi-do, Republic of Korea. Background: Recent update in genome-based technologies revealed many molecular profiles of cancer those can be applied to diagnosis and therapeutic application. However cancer panel test may be a useful tool in aspect of cost-benefit management, such as Oncotype Dx for breast cancer. There is no cancer panel test for pancreas ductal adenocarcinoma. We designed cancer panel test (CancerSCAN TM ) and validated for pancreas cancer. Design: Forty-seven formalin-fixed, paraffin-embedded pancreas carcinoma tissues were assayed on targeted deep sequencing using CancerSCAN TM to investigate mutational profiles of 83 cancer-associated genes. Results: A total of 281 somatic point mutations and small indel were detected at an average of 6 per patient (range 1-14), the majority of which were nonsynonymous mutations (86.1%) including 178 mutations not reported in either COSMIC or TCGA. The most frequently mutated gene was TP53 (n=40, 85.1%), followed by KRAS (78.7%), NOTCH1 (27.7%), SMAD4 (27.7%), BRCA2 (25.5%), NF1 (23.4%), CDKN2A (19.1%), ATRX (17.0%), ARID2 (14.9%), ATM (14.9%), BRAF (14.9%), STK11 (14.9%), respectively. Identified copy number variations were three cases, including deletion of ATRX, CDKN2A and amplification of FGFR3. In total, 103 somatic translocations of genes were detected at an average of 1 per patient (range 0-6). The majority of translocations were inter-chromosomal (n=91). The most frequently translocated gene was TMPRSS2 on chromosome 21 (n=13, 32.5%), followed by EWSR1 (27.5%), BRAF (22.5%), NF1 (17.5%), ATM (12.5%), ROS1 (12.5%), MET (10.0%), respectively. The involved genetically altered core pathways and regulatory processes in pancreatic cancers, we identified 4 groups including KRAS signaling (76.6%), DNA damage control (68.1%), TGF-β signaling (27.7%), and regulation of G1/S phase transition (23.4%). Survival analyses of these groups were statistically insignificant. In addition, there were no significantly associated clinicopathologic features with these groups. Conclusions: This study provides diverse molecular profile of pancreas cancer, known to be important in pancreatic cancer and other genes at low individual prevalence. We found several mutations known as actionable targets to available inhibitors. This study may be applied for clinical applications for customized therapy.
Intraepithelial Neoplasia as a Pitfall in Fine Needle Aspiration of Solid Pancreatic Masses
Jennifer L Dettloff, Pamela J Hodul, Jason Klapman, Cynthia Harris, Mokenge P Malafa, Domenico Coppola, Barbara A Centeno. Moffitt Cancer Center, Tampa, FL. Background: When ductal cells with cytological features of neoplasia are identified in a fine needle aspirate (FNA) of a solid pancreatic mass (SPM), they are presumed to represent pancreatic adenocarcinoma (AdCA). However, we have encountered cases which on resection had intraductal neoplasia, and not AdCA. Here we describe our experience with this subset of cases. Design: Specimens from patients who underwent pancreatic FNA of a SPM that was interpreted as AdCA, whose subsequent resection showed intraductal neoplasia from 10/2008 to 12/2014, were selected. The tumor was entirely submitted. We reviewed the radiology and the FNA focusing on background, cellular architecture, nuclear details and mitoses. Results: Seven patients were identified. The final diagnoses included: 1 neuroendocrine tumor (NET) with dilated PanIN 2, 1 autoimmune pancreatitis (AIP) with high grade intraductal papillary mucinous neoplasm (HGIPMN), 2 intraductal oncocytic papillary neoplasms (IOPN), and 3 HGIPMN. Besides the NET/ AIP, all masses were solid/ cystic and concerning for AdCA on imaging. Histologically, the solid areas correlated with fibrosis and chronic pancreatitis. The FNAs did not show coagulative necrosis or frequent mitoses. Background mucin was present in 2 HGIPMN and in the 2 IOPN. Abundant acute inflammation was seen in 2 HGIPMN. All cases showed crowding, loss of polarity and anisonucleosis. Feathering was a frequent finding. Two cases of HGIPMN showed single signet ring-like cells and small tufts, which histologically correlated with sloughing of the luminal epithelium. Both IOPN had single oncocytic cells, clusters and papillae. Cell blocks of both IOPN and of 1 HGIPMN showed papillary fronds lined by neoplastic cells in a clean background. The NET (0.7 cm) was not sampled, but the PanIN 2 showed cohesive clusters with pale chromatin, peripheral nucleoli, smooth nuclear membranes, and significant anisonucleosis. The remaining cases showed cohesive clusters, with enlarged nuclei, nuclear angulation, grooves, pale chromatin, and increased N/C. Conclusions: Intraductal neoplasia may occur with a solid mass, such as AIP and NET, and can produce cytological features similar to those of AdCA. Single cells were not a reliable indicator of invasion. A solid component associated with a cystic mass is not always invasive cancer. Oncocytic neoplasms were problematic in our series. An intraductal component should be considered when there are well defined papillae, and when necrosis is absent. All patients had disease requiring resection and neoadjuvant therapy was not used, hence there was no impact on patient care.
SMAD4 Inactivation as Assessed by Diligently Evaluated Immunohistochemistry Is Highly Associated with Adverse Prognosis in Pancreas Cancer
Craig Dunseth, Sarah L Mott, Jason Hornick, James J Mezhir, Andrew M Bellizzi. University of Iowa, Iowa City, IA; Brigham and Women's, Boston, MA. Background: SMAD4 inactivation is frequent in pancreatic ductal adenocarcinoma (PDA), and SMAD4 immunohistochemistry (IHC) is a reliable surrogate to molecular analysis. Although several studies have suggested that SMAD4 inactivation is indicative of adverse prognosis, one large study found the contrary, such that a recent meta-analysis concluded that SMAD4 represents a "non-significant biomarker." The goal of this study is to verify SMAD4's prognostic significance. Design: Tissue microarrays were constructed from 248 primary and 97 metastatic PDAs. SMAD4 IHC was performed with a monoclonal antibody (clone B-8, Santa Cruz, 1:100). Tumors were scored as intact (any cytoplasmic and/or nuclear staining) or lost (completely absent staining). Detailed clinical annotation was available for 168 tumors. For these, survival probabilities were estimated using the Kaplan-Meier method. Cox proportional hazards regression was used to assess the effects of clinicopathologic variables on progression-free (PFS) and overall survival (OS). Estimated effects are reported as hazard ratios (HRs) with 95% confidence intervals (CIs). All statistical testing was two-sided and assessed for significance at the 5% level. Results: SMAD4 loss was detected in 34% of 232 primaries and 40% of 83 metastases (9% attrition). SMAD4 status was concordant in 88% of primary-metastatic pairs. SMAD4 loss in the primary was prognostically adverse on univariate and multivariate analyses of OS and PFS. Multivariate results are presented in the Tables. Table 1 Overall Conclusions: SMAD4 loss in primary PDA doubles a patient's risk of death. The hope is that this result will clear the way for the use of SMAD4 evaluation in future clinical trial design and assessment.
Comparative Clinicopathologic Study of Biliary Intraductal Papillary Neoplasms and Papillary Cholangiocarcinomas
Kohei Fujikura, Tomoo Itoh, Yoh Zen. Kobe University, Kobe, Hyogo, Japan. Background: Intraductal papillary neoplasm of the bile duct (IPNB) has been widely accepted as a unique form of biliary neoplasm. However, the definition of IPNB remains to be standardized, as some pathologists call nearly all papillary neoplasms arising in the bile duct as IPNB, while others consider this diagnostic term for selected cases Design: Papillary neoplasms of the bile duct were provisionally classified into two groups. IPNB was defined as biliary neoplasms that are regularly arranged in a high-papillary architecture along thin fibrovascular stalks, while the term "papillary cholangiocarcinoma (papillary CC)" was used for papillary adenocarcinomas that show predominantly intraductal growth but do not fit with IPNB because of their complex histologic architectures (e.g., mixed with solid-tubular growth or thick papillae). Clinicopathological features were compared between IPNBs (n=20) and papillary CCs (n=27) using immunohistochemistry and mutation analyses for KRAS and GNAS. Results: In a consecutive cohort of primary biliary neoplasms in our institute, 15% showed predominantly intraductal papillary growth. About 1/3 of them (4.5% of the total) was IPNBs, while the remaining 2/3 (10%) were classified as papillary CCs. A majority of IPNBs were located in intrahepatic (60%) or hilar (35%) bile ducts, while papillary CCs occurred in extrahepatic (81%) or hilar (19%) ducts (p<0.001).
Gross mucin was more commonly found in IPNBs than in papillary CCs (80% vs. 7%, p<0.001). In terms of tumor cell types, pancreatobiliary and intestinal type neoplasms were noted in both groups, while gastric and oncocytic type tumors were found only in IPNBs. Unlike papillary CCs, 48% of which had deep invasion beyond the duct wall, 60% of IPNBs were non-invasive or minimally invasive carcinomas. Immunophenotypes of tumor cells were also significantly different between the two categories particularly in terms of MUCs and CK20. A clustering analysis based on expressions of MUCs and CKs demonstrated two dominant clusters that were highly specific for either condition. Disease-free 5-year survival rates were around 81% for patients with IPNB and 40% for those with papillary CC (p=0.03). KRAS and GNAS appeared to be wild-type genotypes in all but one case of KRAS-mutated IPNB Conclusions: Given the significant differences in clinicopathologic features between the two groups, the diagnostic term "IPNB" may be used for selected tumors that show regularly arranged papillary growth, separately from papillary CC. Of the 66 with imaging available, 9 were disqualified from being CC by Japanese criteria, and of the 39 with pre-op cyst typing, 10 were re-typed. 12 had been labeled "PB maljunction"; none had received ERCP (part of routine workup in Japan). 15 had features of duplication [separate duct on the wall(11) or complete muscular coat(4)]. One proved to be duodenal diverticulum. Pathologic findings: Mucosal hyperplasia-36 (43%): prominent glandular pattern-14, papillary configuration-4, peribiliary mucous gland hyperplasia-11; intestinal metaplasia-9; hyperplastic pseudostratification resembling BilIN-1/2(LGD)-14. Duct-centric lymphoplasmacytic inflammation-40 (dense-5, follicular-6); ulceration/erosion (with PMNs/granulation)-11; severe atypia mimicking dysplasia-9. High-grade dysplasia of non-tumoral type (BilIN-3/CIS) w/o invasion-7. One had intraductal papillary neoplasm (IPNB) with HGD w/o invasion. Invasive carcinoma in 6, all tubular/pancreatobiliary type. Cyst size was documented in 76: all 14 HGD/ca cases were in cysts >1 cm, and none of the 10 cysts <1cm had HGD/ca.
Conclusions:
What is clinically designated as CC in the US is heterogenous pathologically, including duplications, mere dilatation of native ducts, even duodenal diverticula. There are substantial differences in the definition of CC in the East vs. West; about 15% of the cases in the US do not fulfill the Japanese criteria. CCs often show mucosal hyperplasia, duct-centric inflammation and atypia mimicking dysplasia. Carcinomatous change is seen in 16%; HGD/CIS (w/o invasion) in 8%, IPNB in 1%, and invasive carcinoma in 7%, thus resected CCs ought to be examined carefully to exclude these lesions. Background: In the current 7 th American Joint Committee on Cancer (AJCC) staging system, gallbladder involvement of distal cholangiocarcinoma is defined as a T3. While, primary carcinoma of the cystic duct is applied not for extrahepatic bile duct cancer but for gallbladder cancer staging in the 7 th edition AJCC system. The aim of this study was to investigate clinicopathological and prognostic significances of cystic duct and gallbladder invasion on the distal cholangiocarcinoma. Design: A total of 200 patients with distal cholangiocarcinoma from May 2010 to June 2012 were collected from a single institution and compared with various clinicopathologic variables, including survival. Results: Distal cholangiocarcinoma involved the pancreas (117/200, 59%), duodenum (54/200, 27%), and/or cystic duct (37/200, 19%) . There was no invasion of gallbladder. In patients with cystic duct invasion, concomitant pancreatic and/or duodenal invasion was identified in 38% (14/37). Cystic duct invasion was associated with epicenter in mid common bile duct (p < 0.0001), resection marginal involvement (p = 0.001), and frequent nodal metastasis (p = 0.031) in distal cholangiocarcinoma patients. Median survival time of patients with and without cystic duct invasion was 25.1 months and 36.8 months, and there was no significant survival difference based cystic duct invasion (p = 0.254). But patients with pancreatic or duodenal invasion demonstrated significantly worse survival than those without pancreatic (p < 0.0001) or without duodenal invasion (p = 0.002), respectively. In the patients with cystic duct invasion, median survival time of those with and without concomitant pancreatic and/or duodenal invasion was 17.5 months and 43.1 months, respectively. The survival for patients with cystic duct invasion was not significantly different whether or not there was concomitant pancreatic and/or duodenal invasion (p = 0.065). Conclusions: Although gallbladder invasion was not observed in distal cholangiocarcinoma, cystic duct invasion was observed in subset of distal cholangiocarcinoma patients. Distal cholangiocarcinomas with cystic duct invasion tend to have more lymph nodal invasion and margin positivity, but do not show prognostic significance like pancreatic and/or duodenal invasion. 
ATRX/DAXX

Conclusions:
This finding is congruent with some of the previous investigations of the predictive value of hENT1 expression in resected PDAC treated with AdjCTx. However, the addition of MMR status suggests that there may be a synergistic effect with regard to treatment response and that its inclusion into the emerging mosaic of predicitve biomarkers in PDAC has served to potentially identify a small group (7%) of hENT1+ cases and a larger group of MMRp cases (30%) that do not benefit from AdjCTx. This result suggests that this population of non-responders should be triaged for trials using novel targeted molecular therapeutics. Background: Cellular interactions in the tumor microenvironment, including tumorstroma interactions, play a major role in the neoplastic progression of many cancer types. This is especially true for pancreatic ductal adenocarcinoma (PDAC) which to date remains a highly lethal malignancy with rising incidence, characterized by a rich stromal component and treatment resistance. The presence of dissociative growing cancer cells (coined "tumor budding cells") at the tumor-host interface is an adverse prognostic factor in PDAC. Tumor budding phenotype shares molecular similarities with the experimental phenomenon of epithelial mesenchymal transition (EMT). Design: Each six PDACs with and without EMT-like tumor budding phenotype (n=12) were studied. Of each specimen, RNA was extracted from main tumor, EMT-like cancer cells ("tumor budding cells") as well as juxta-tumoral and tumor-remote stroma, after laser capture microdissection of membrane slides. The expression of miR21, miR-210 and miR200b, miR-183, miR-203, miR-205 and miR-2017 was examined by qRT-PCR, using a pre-amplification protocol. Material from corresponding normal pancreatic tissue was used for normalisation. Results were compared with immunohistochemical markers of EMT. Results: In PDACs with EMT-like tumor budding phenotype, miR-21 and miR-210 were overexpressed while miR-200b was downregulated by main tumor cells, EMT-like tumor budding cells and juxta-tumoral stroma compared to matched normal tissue. In cases without EMT-like tumor budding phenotype miR-21 was also overexpressed in main tumor cells as well as in stromal cells, but intersestingly, miR-200b and miR-210 showed the opposite picture with overexpression of miR-200b and reduced expression of miR-210. The expression of miR-200b showed a negative correlation with the ZEB1 protein expression in tumor and stromal cells. The expression of all other miRs was not found to be dysregulated. Conclusions: Differential microRNA expression by tumor and stromal cells within the tumor microenvironment of the invasive front of pancreatic cancer may influence the PDAC phenotype by regulating EMT-like tumor budding. Our findings underline the importance of epigenetic regulation in the tumor microenvironment of PDAC and emphasize the need for developing novel targeted and individualized therapies for PDAC patients including microRNA-interference.
Alternative Lengthening of Telomeres in Pancreatic Carcinomas with Acinar Differentiation
Jiyoon Kim, Jacqueline Brosnan-Cashman, Soyeon An, Do Youn Park, Haeryoung Kim, Young-Ha Oh, Ralph H Hruban, Christopher M Heaphy, Seung-Mo Hong Background: Pancreatic carcinomas with acinar differentiation are extremely rare and have a poor prognosis. Telomeres are maintained as neoplasms progress predominantly by activation of telomerase, and less commonly by the recombination-dependent alternative lengthening of telomeres (ALT) pathway. Activation of the ALT pathway has been observed in a variety of human cancers, including pancreatic neuroendocrine tumors, osteosarcomas, and glioblastomas. Carcinomas with acinar differentiation have not been previously evaluated for the presence of the ALT phenotype. Design: Across 4 institutions, we collected 28 pancreatic carcinomas with acinar differentiation; 14 acinar cell carcinomas (pure ACCs) and 14 mixed acinarneuroendocrine carcinomas (mixed ACCs), and constructed tissue microarrays. We performed telomere-specific fluorescent in situ hybridization to determine the ALT status of each case and correlated the results with clinicopathologic factors. Results: ALT-positivity (ALT+) was observed in 18% of the carcinomas (5/28 cases; 1 pure ACC and 4 mixed ACCs), and ALT+ was more common in carcinomas without necrosis (p=0.059). However, ALT+ cancers were not associated with other clinicopathologic factors, including age and sex of the patients, growth pattern (expanding vs. infiltrating), tumor size, pT classification, and lymphovascular and perineural invasions. Interestingly, patients with ALT-positive tumors had better recurrence-free survival (median survival time, 71 months) than those with ALT-negative tumors (9 months) with marginal significance (p=0.06).
Conclusions:
The ALT+ phenotype is observed in a subset of pancreatic carcinomas with acinar differentiation, including pure ACC and mixed ACCs, and these patients tended to have a better survival time than patients with ALT negative tumors. (ALT) is a telomerase-independent pathway for telomere maintenance in a subset of human cancers. Previous studies have demonstrated that the presence of the ALT pathway in pancreatic neuroendocrine tumors (PanNETs) is strongly associated with alterations in two chromatin remodeling proteins, ATRX and DAXX, and increased chromosomal instability. Design: Telomere-specific fluorescent in situ hybridization was performed to determine the ALT status in a cohort of 278 surgically resected PanNETs. ALT status was compared with clinicopathologic factors. Results: Overall, ALT-positive tumors were observed in 54 cases (19.4%). ALT-positive PanNET tumors were higher WHO grade, larger in size, and of higher pT stage than were ALT negative PanNETs. ALT positivity also correlated with lymphovascular and perineural invasion, lymph node and distant metastases, and patients with ALT+ primary PanNETs had a shorter recurrence-free survival. Interestingly, patients with distant metastases had significantly better survival when the tumors were ALT-positive compared to those with an ALT-negative tumor. Conclusions: Primary ALT-positive PanNETs are associated with aggressive clinicopathologic behavior and have poor recurrence-free survival. Once ALT-positive clones establish as a metastatic foci, these cancers appear to grow more slowly in the new microenvironment, as patients with ALT+ tumors have a better prognosis than those with ALT negative. Background: NAT is recommended to increase feasibility of margin-negative(R0) resections in BRPC. Extent of residual tumor in posttreatment pancreatectomy specimens can be classify by proposed College of American Pathologists(CAP) and/or Evans grading systems, but which is more predictive of outcome for BRPC following neoadjuvant CT(NACT) w/o radiation (RT) is unknown. Design: We conducted a retrospective review of 32 BRPC pts treated with NACT w/o RT followed by resection between 2010-2015. Log-rank test was used to test the association between pathologic response, comparing CAP and Evans grading systems, and patterns of recurrence and survival outcomes. Results: Majority of pts (22) received neoadjuvant FOLFIRINOX(68.8%) vs gemcitabine-based regimens(31.2%). Overall, 28 pts(87.5%) achieved R0 resection and 18(56.3%) had node-negative disease. Angiolymphatic invasion, perineural invasion, and direct extension into adjacent structures were seen for 8(25%), 20(62.5%), and 22 pts(68.8%), respectively. With a median f/u time of 29.8 mo, 15 pts(46.9%) relapsed; including 8(53.3%) with both locoregional and metastatic recurrence. By Kaplan-Meier analysis, median disease-free(DFS) and overall survival(OS) are 22.5 and 34.2 mo, respectively. Final pathologic tumor stages: ypT0=3.1%, ypT1=18.8%, ypT2=6.3%, ypT3=65.6%, and ypT4=6.3%. One pt(3.1%) had pathologic complete response(CAP 0, Evans IV). Remaining grades classified: CAP 1=12.5%, 2=56.3%, and 3=28.1%; vs Evans I=21.9%, IIa=21.9%, IIb=25%, and III=28.1%. Both systems showed statistically significant associations with clinical outcomes (CAP: p=0.014 and p=0.002 for OS and DFS, respectively; Evans: p=0.003 and p=0.031). When each grading system was stratified into two tiers (CAP 0/1/2 vs CAP 3, and Evans I/IIa/IIb vs Evans III/IV), stratified CAP showed stronger statistical association for both OS(p=0.0023) and DFS(p=0.0002) than Evans(p=0.041 and p=0.112).
Alternative Lengthening of Telomeres in Primary Pancreatic
Neoadjuvant Therapy (NAT) for Borderline Resectable Pancreatic Cancer (BRPC): Comparison of Histologic Grading Systems of Residual Adenocarcinoma Following Chemotherapy (CT) Alone
Conclusions:
In this limited unique cohort of BRPC treated exclusively with NACT, pathologic response by both CAP and Evans grading systems is predictive of clinical outcomes. When each system is stratified into two tiers, CAP appears to be the superior method in terms of strength of statistical association with both OS and DFS.
Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells
Heidi D Lehrke, Rondell Graham, Dora Lam-Himlin, Robert R McWilliams, Thomas C Smyrk, Lizhi Zhang. Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ. Background: Pancreatic carcinoma is an aggressive malignancy with a dismal prognosis; thus, identification of novel effective therapies is clinically important. Studies have shown that expression of PD-L1 by tumor cells may predict response to targeted PD-1/PD-L1 inhibition. While pancreatic carcinomas have shown PD-L1 expression, the extent of PD-L1 expression has not been reported in detail and unselected conventional pancreatic ductal adenocarcinomas (cPDAC) have shown limited clinical responsiveness to anti-PD-L1 therapy. Specifically, detailed histologic analysis of undifferentiated pancreatic carcinomas for PD-L1 expression compared to cPDAC has not been performed. Design: We identified 20 cases of undifferentiated pancreatic carcinoma (UPC) and 36 controls of conventional pancreatic adenocarcinoma (cPDAC). The cPDAC group included 8 well, 14 moderate, and 14 poorly-differentiated tumors. Immunohistochemistry for PD-L1 (E1L3N clone), CD3, CD20, CD68 and mismatch repair proteins was performed. Slides were scored for extent of membranous PD-L1 expression on tumor cells with ≥1% being positive. Correlations were examined by Fisher's exact test. Results: PD-L1 expression was more frequent in UPC (n=10) than cPDAC controls (n=6) (50% vs 17%; p=0.01). The extent of PD-L1 expression was greater in UPC with 9 of 10 cases showing ≥10% tumor cells positive compared to 3 of 6 cPDAC controls (2 of which were poorly differentiated). UPC were characterized by sheets of pleomorphic tumor cells with frequent tumor giant cells and spindle cell areas; osteoclast-like giant cells were variably present (n=6). Gland formation was absent. Tumor infiltrating lymphocytes were not brisk in any UPC case. There was no histologic difference between UPC with or without PD-L1 expression. Each MSI-H tumor (n=3) showed PD-L1 expression including 2 UPC and 1 cPDAC. Correlation of PD-L1 expression with disease-specific survival is currently being analyzed. Conclusions: UPC is enriched for PD-L1 expression both in frequency and extent relative to cPDAC controls. Our data also show that higher grade cPDACs are associated with an increased frequency of PD-L1 expression. We propose that the histologic subtype and tumor grade may aid in the selection of patients who have an increased likelihood of response to anti-PD-L1 and PD-1 therapy. Analysis of a larger cohort of UPC and control cases for validation of these findings is ongoing. Jochen K Lennerz, Charlotte I Wang, Leona Doyle, Tiffany G Huynh, Neal Lindeman, Amitabh Srivastava, Carlos Fernandez del-Castillo, Mari Mino-Kenudson. Massachusetts General Hospital and Harvard Medical School, Boston, MA; Brigham and Women's Hospital, Boston, MA. Background: The oncocytic subtype of intraductal papillary mucinous neoplasia (IPMN-o) is generally regarded as a clinically indolent subgroup. However, recurrences have been described. Here we compared the clinical and molecular profiles of nonrecurrent and recurrent IPMN-o. Design: We identified 13 IPMN-o by an archival search and macrodissected different areas from the same tumor (N=3 non-recurrent; N=1 recurrent) and comparison between original and recurrent (N=4 recurrent cases) to assess spatial and temporal heterogeneity. Genotyping was performed using the OncoPanel assay that by massively parallel sequencing using a solution-phase Agilent SureSelect hybrid capture kit and an Illumina HiSeq2500. We performed contingency testing by recurrence status and plotted key oncogenic as well as recurrent variants (found in more than one patient). Results: 7/13 IMPN-o patients had a tumor recurrence as IPMN-o. Contingency testing between the two groups did not show significant differences (P-range: 0.46-1.0). Genotyping identified a total of 133 variants with a median of 6 variants/sample. The overall mutational burden was higher in the recurrent group (median: 12; range: 2-19) when compared to the non-recurrent group (median: 6.5, range 1-15) but this did not reach statistical significance (P=0.37; t-test). A mutually exclusive pattern of driver gene variants was seen in IMPN-o as well as the presence of additional variants in genes frequently mutated in pancreatic ductal adenocarcinoma (PDAC).
Mutational Profiling of Oncocytic Intraductal Papillary Mucinous Neoplasms (IPMN-o)
Comparison of the mutational pattern in recurrent lesions with the original IPMN-o revealed no consistent pattern, suggesting tumor heterogeneity. Given that all surgical excisions were initially complete (R0), the spatial (intratumoral, assessed in 4 of 13 cases) and temporal heterogeneity (between initial and recurrent lesions, assessed in 4 of 7 recurrent cases) suggests a mutational field effect affecting the pancreatic ductal tree.
Conclusions:
Genotyping of IPMN-o shows key driver mutations as the principal pathogenetic pathways of pancreatic neoplastic progression and lack of a consistent mutational spatial or temporal spectrum suggest significant intratumoral heterogeneity. R132H IHC on all cases with appropriate controls. Tumor cell nuclear positivity from 5 high power fields was recorded and cases with more than 5% of cells staining were considered positive. Pyrosequencing for IDH1 was also performed in parallel on FFPE from each case. Results: The average tumor size was 6.3 cm and the majority of cases were unifocal (n=26) within the hepatic parenchyma with a tumor stage of T1 (n=15), T2 (n=5) or T3 (n=9). Background liver demonstrated no significant abnormality (n=3), cholestasis (n=5) with mild to moderate portal inflammation (n=16) and/or macrovesicular fatty change (n=12). All 29 cases were negative for IDH R132H staining by IHC. However, 2 cases (7%) had IDH1 mutations c.394C>T (p.R132C) and c.394C>A (p.R132S) by pyrosequencing. Conclusions: IHC specific for the IDH1 R132H altered protein has proven useful in gliomas; a recent large study showed that 83% of IDH1 mutations are c.395G>A (p.R132H). However, both mutations found in our ICC cohort were for a different nucleotide (c.394) and resulted in different amino acid substitutions. While a larger cohort is needed to fully map the range of IDH mutations in ICC, our results suggest that IHC may not be useful for screening ICC. If IDH1 status is needed for clinical trial enrollment or prognostication, sequencing is more likely to identify the mutations present. were not significantly different between the two groups. Certain genes were not mutated in the three MMR-mutated PNETs that were mutated in a subset of non-MMR PNETs (PTPRD, PLCH2, COL1A1, HIF1A, NBN and KAT6A), but these differences were not statistically significant in this small study.
Morphologic Characterization of Intrahepatic
Conclusions:
In this cohort, MMR-mutated PNETs were more common than previously reported and have a distinct mutational profile compared to non-MMR PNETs. Study of additional MMR-mutated PNETs will determine whether this subset of tumors has a different prognosis or responds differently to therapy than non-MMR PNETs. Conclusions: Pathologic sub-staging of T2 GBCs has significant prognostic value. The outcome of early/limited T2 cases (< 1.5 mm peri-M inv) is very good (5-year, 90%), closer to that of "EGBC" (Tis/T1) GBCs (PMID: 24022828); whereas, of those approximating the GB serosa, is dismal (5-year < 20%). There does not seem to be any significant geographic difference in the frequency of sub-stages (similar in Chile vs US). Nodular, pushing-border growth pattern was consistent, and 5 were arising in tumoral intraepithelial neoplasms (4 in MCN, 1 in IPMN) and 11 (55%) also showed prominent intraductal/cystic growth. Osteoid was seen in 7. LVI in 11 and PNI in 6. 15 (75%) had an invasive ductal/tubular adenoca (DA) component that ranged from microscopic to 80% of the tumor (mean, 23% In order to clarify the pathological features of such cases, we carried out this study. Design: 19 resection specimens with a pathological diagnosis of type 1 AIP were gathered. Hematoxylin and eosin-stained slides were evaluated on histological features of the duct system and lobules, and the presence or absence of peripancreatic inflammation and obliterative phlebitis. Results: We identified 3 cases in which pancreatic ducts were selectively involved and pancreatic lobules were markedly atrophic (duct-centered type). Through the histological review, we identified two histological types of pancreatic duct lesions; one with a thick cuff composed of concentric infiltration of inflammatory cells without preexisting collagenous stroma (concentric pattern), and the other with lymphoplasmacytic infiltration partly involving the preexisting structure (diffuse pattern). All the 3 cases with the duct-centrered type showed the concentric pattern in the main duct and wall edema at the peripheral ducts. Pancreatic acinar cells in the lesions were almost completely absent in all of these cases, and peripheral ducts partially disappeared in 2. Inflammatory cells were scarce in the destructive lobules and peripancreatic region except for one case in which numerous lymphoid follicles were formed. Obliterative phlebitis was seen in only one case. Two other cases with the concentric duct pattern and 14 with the diffuse pattern revealed lobular and peripancreatic inflammation, of which the formers were more severely inflamed, and obliterative phlebitis was identified in every case.
Ly m p h N o d e Y i e l d a n d E x c i s i o n M a rg i n S t a t u s i n
Conclusions: This study indicates that there is a histological subtype of type 1 AIP in which inflammation was confined to the duct system causing a massive lobular effacement. This subtype may represent some type 1 AIP cases in which pancreatic atrophy occurs after steroid treatment. The concentric pattern of the duct lesions may be one reason why the lobules are markedly atrophic.
The Diagnostic Utility of Pancreatic Biopsy for Inflammatory Bowel Disease-Associated Pancreatitis
Kenji Notohara, Shigeyuki Kawa, Toshiharu Ueki, Atsushi Kanno, Mamoru Watanabe, Tooru Shimosegawa. Kurashiki Central Hospital, Kurashiki, Japan; Shinshu University, Matsumoto, Japan; Fukuoka University Chikushi Hospital, Fukuoka, Japan; Tohoku University, Sendai, Japan; Tokyo Medical and Dental University, Tokyo, Japan. Background: Type 2 autoimmune pancreatitis (AIP) is known to occur in patients with inflammatory bowel disease (IBD), but other causes of pancreatitis, such as adverse drug reactions, may also be involved. In most studies to date, investigation has been based on the histology of resected tissues or on clinical observations, with little discussion on biopsied tissues. In order to clarify the diagnostic utility of biopsy, we conducted a study with specimens gathered by a nationwide survey in Japan. Design: Cases with both IBD and pancreatitis were gathered from members who belonged to reseach committees for Intractable Pancreatic Disease and Intractable Inflammatory Bowel Disease in Japan, respectively. Clinical information was gathered by a questionnaire, and histological slides were submitted for reevaluation. The histological patterns were classified based on a combination of types of predominant epithelial changes [A: remaining of acinar cells, B: acinar-ductal metaplasia (ADM), C: loss of the majority of the epithelium] and types of stroma and inflammatory infiltration (0: edema without inflammatory cells, 1: inflammatory cell infiltration, 2: fibrosis). A primary and, if present, a secondary pattern were recorded for each case. Intraglandular neutrophilic infltration (INI) was also evaluated. Results: 23 patients, 18 with ulcerative colitis (UC) and 5 with Crohn's disease (CD), were included. The B-1 pattern was most frequent, and was observed in 9 patients as a primary and a secondary pattern, respectively. The C-1 pattern was secondarily more common, and was found in 8 patients. There was ADM with INI in 11 patients, with one patient having additional INI in the genuine duct (granulocytic epithelial lesion). The Pattern 2 (fibrosis) was seen in 5 patients, and was more common in CD (2/5) than in UC (3/19). In one patient, eosinophils instead of neutrophils were found in the edematous lobules, suggesting an adverse drug reaction. Cytomegalovirus (CMV) inclusion was identified in another case. ); ∆Cq was defined as the difference between the Cq value of the target miRNA and that of the internal control (Cq miRNA-Cq RNUB6).
Results:
The study and control group consisted of 11 patients (M:F = 2:9; age 60.4±8.1 years) and 8 patients (M:F = 1:1; age 73.1±6.9 years), respectively. Patients in the study group developed metastasis to the lung (4), liver (3), abdominal wall/ peritoneum (3), and bone (1). The miRs in both groups had similar expression patterns: miR-10b (underexpressed), miR-21 (overexpressed), miR-148a (inconsistent), miR196a (underexpressed) , and miR-217 (underexpressed). Further semi-quantitative stratification of the miR expression (based on the Cq value) also did not show any significant difference between the two groups. Conclusions: Expression patterns of miR-10b, miR-21, miR-148a, miR-196a, and miR-217 in PDAC were not predictive of distant metastasis following neoadjuvant chemoradiation. Further studies are necessary to look for novel markers to predict the biological aggressiveness of PDAC.
Impact of Training and Experience on Evaluation of Biliary Brushings (BDB)
Michelle Reid, Ezgi Hacihasanoglu, Vaidehi Avadhani, Adeboye O Osunkoya, Uma Krishnamurti, Krisztina Z Hanley, Alyssa Krasinskas, Lauren Daniels, Alexa Freedman, Michael Goodman, Volkan Adsay. Emory University, Atlanta, GA. Background: While the low sensitivity and accuracy of BDB in assessing biliary pathology is well known the role of cytology training and signout (s/o) experience in this organ system has not been analysed. Design: We evaluated impact of cytology training and GI pathology (GIP) experience on diagnosis (Dx) of 60 BDBs among 7 reviewers (3 board-certified cytologists (CYTOs) w/ 7, 10 and 11 yrs experience respectively, 2 GIPs (one w/o BDB s/o experience (GIP1); and 1 w/ (GIP2), 1 generalist (GEN) w/o CYTO/GI training, and a CYTO fellow). BDBs included 30 malignant (w/ histologic confirmation) and 30 benign (w/ resection/≥18 mths uneventful f/u). For the purpose of testing agreement, the Dxs rendered were compared to the consensus Dx made by at least 2 of 3 CYTOs.Interobserver agreement (IOA) was poor to fair (K 0.13-0.39) with fellow and CYTOs showing greatest agreement and GIP1 and CYTOs showing least (poor). IOA between 3 CYTOs and between GIPs was also fair. Conclusions: Among pathologists, the level of IOA in evaluating BDBs is fair regardless of experience. While cytology training is associated with higher specificity in diagnosing malignancy this is at the expense of sensitivity, and suggests that CYTOs are more cautious in diagnosing malignancy unless the evidence is overwhelming. In contrast GIPs are more prone to calling things malignant (higher sensitivity) but with lower specificity. Experience in GI appears to improve overall performance of cytopathologists in evaluating BDB. Conclusions: A significant proportion of cases designated as Tis (HGD/CIS/noninvasive) in the US would be diagnosed as T1/T2 in S. America and Asia. This suggests the need for the more unifying category of EGBC (Tis+T1), which is already being used in high risk regions, which essentially corresponds to the "intramucosal adenocarcinomas" of other GI organs, and it has been shown in international collaborative studies (with Western criteria) to have a 10-year survival of 90% (if T2 carcinoma is excluded by total GB sampling; PMID:24022828). In order to bridge the geographic gaps identified in this study, a sub-classification of these EGBCs by an approach similar to the Vienna classification for early gastric cancers was proposed at the Santiago meeting and is currently being tested for applicability.
Interpretation of experts from other continents on cases uniformly designated as noninvasive by 7 Pathologists trained in the US
Stromal Changes Related to Therapy in Pancreatic Cancer
Daniel Rowan, Kiyoko Oshima. Medical College of Wisconsin, Milwaukee, WI. Background: Dense desmoplastic stroma is a histologic hallmark of pancreatic cancer; however, it has received little attention until recently. Despite the recent success of chemotherapies, the survival benefit is modest. The poor survival benefit is attributed to poorly delivered chemotherapeutic agents due to hypovascular stroma composed of SMA positive activated (myofibroblastic) pancreatic stellate cells. Therefore, the focus of treatment has recently shifted from cancer cells to stroma. Preliminary data on stromal modification has shown contradictory results. Histologic changes in stroma related to treatment have not been described well in pancreatic cancer. The aim of this study is to assess the stromal response to neoadjuvant therapy and to correlate findings with residual tumor cellularity.
Design: We retrospectively reviewed slides from 93 patients (15 without neoadjuvant therapy (NoNeo), 78 with neoadjuvant therapy (Neo)) who underwent pancreatectomy for ductal adenocarcinoma from 2009 to 2014. Amount of collagen and myofibroblastic stroma were scored from 0-4 (1+: 1-25%, 2+:26-50%, 3+:51-75%, 4+:76-100%). Inflammation was scored from 0-2 (1+: 50-500 cells/10 hpf, 2+: >500 cells/hpf). Presence of neural hyperplasia was recorded. Arterial changes were scored from 0-3 (1+: 1 artery with change, 2+: 2-3 arteries, 3+:4-5 arteries). The most representative tumor slide was selected from 56 cases, and each slide was scanned with a scanning system. Area of fibrosis and tumor were selected and tumor stroma ratio (TSR=area of tumor mm 2 /area of fibrous bed mm 2 x 100%) was calculated. ANOVA, Chi-square, and t-tests are used for statistical analysis. Results: Average collagen scores in the NoNeo and Neo groups were 2.53±0.83 and 2.07±0.77. Collagen score was significantly lower in the Neo group (p=0.02). Average myofibroblastic stroma scores in the NoNeo and Neo groups were 1.80±0.77 and 2.36±0.81. Myofibroblast score was significantly higher in the Neo group (p=0.01). Arterial changes and neural hyperplasia were more frequent in the Neo group (p=0.0004, 0.0008). TSR minimal (0-2%), mild (2-6%), moderate to high (>6%) cases showed myofibroblast dominant cases as follows: 4/12 (25%), 11/21(52%) and 12/20(60%). Cases with more residual tumor showed more myofibroblast predominant stroma (p=0.04). There were no significant differences in inflammation between the two groups. Conclusions: Myofibroblastic stroma is increased after neoadjuvant therapy, and treated tumors with higher residual cellularity are associated with higher myofibroblast scores. This suggests that myofibroblasts may contribute to therapy resistance. Background: Tumour hypoxia is attributed to the aggressive biology of pancreatic ductal adenocarcinoma (PDAC). We previously reported correlation of hypoxia with rapid tumour growth and metastasis in patient derived xenografts (PDX). We subsequently initiated Pimo-Panc trial (NCT01248637), where patients with resectable PDAC receive pre-operative pimonidazole. Anticipating a prognostic relevance of hypoxia, we developed protocols for semi-quantitative image analysis (IA) to provide objective observer-independent measures of hypoxia. We are evaluating the concordance of microenvironmental features in PDXs with those of the patient tumour. Design: Pimonidazole IHC was performed on patient tumours. Hypoxic percentage (HP) in the epithelial and stromal compartments was obtained by analysis of IHC using 3 IA platforms based on pattern-recognition software; Definiens-Developer, Tissue Studio and Aperio's Genie. Sections from corresponding PDX models were analyzed similarly.
Results:
The 3 IA platforms demonstrated HP in the range of 0-30% in the tumour, with higher levels of HP in epithelial (range=0-25%) vs stromal (range= 0-5%) compartment. Higher levels of HP were obtained by Genie vs Definiens, however HP rank ordered similarly. Furthermore, PDX models recapitulated the morphology in corresponding patient tumour. Mean HP in each patient and PDX was concordant. There was intratumoural heterogeneity in HP in the PDAC but not in PDXs.
Conclusions: Assessment of hypoxia in PDAC and corresponding PDXs using semiquantitative IA is novel. The concordance of HP in PDX and patient tumour suggests these are highly relevant to study hypoxia-related tumour biology as well as diagnostic and therapeutic modalities. Aatur Singhi, Jinru Shia, Marina Nikiforova, Jason L Hornick, David Klimstra, Sapna Syngal, Beth Dudley, Randall E Brand, Herbert J Zeh, Ralph H Hruban Background: Although most pancreatic ductal adenocarcinomas (PDACs) are sporadic, ~10% may be due to an inherited syndrome. A subset of PDACs occurs in patients with Lynch syndrome; these cancers are particularly important to identify, given the growing impact of immunotherapy for mismatch repair (MMR)-deficient cancers. The goal of this study was to assess the histopathology, precursor lesions and genetic profile of PDACs arising in patients with Lynch syndrome. Design: Nine resected PDACs from patients with Lynch syndrome were collected from 3 institutions. For each case, clinical information, gross findings and histologic sections were evaluated. Alterations in PDAC-associated genes were assessed by next generation sequencing and fluorescence in situ hybridization. Immunohistochemistry for Smad4 and the MMR proteins was also performed. Results: The 5 females and 4 males ranged in age from 50 to 81 years (mean, 65.3 years). Six (67%) had a prior history of Lynch syndrome-associated cancers and 3 (33%) reported a family history of malignancy. Germline Lynch syndrome-associated alterations included: MSH2 (n = 5), MSH6 (n = 3) and MLH1 (n = 1). The patients' tumors were predominantly located within the pancreatic body and/or tail (n = 8, 89%) and ranged in size from 0.5 to 14.0 cm (mean, 4.9 cm). Histologically, 7 (78%) were classified as tubular-type PDACs and the remaining were adenosquamous (n = 1) and medullary (n = 1). An associated intraductal papillary mucinous neoplasm (IPMN) was present in 6 (67%) cases. Four IPMNs were available for MMR immunohistochemistry and all lost expression of the protein corresponding to the germline MMR alteration. The PDACs were staged as follows: 1 was pT2N0, 3 pT3N0 and 5 pT3N1. Genetic profiling of all PDACs revealed somatic alterations in the following genes: KRAS (n = 6), GNAS (n = 4), TP53 (n = 3), and PIK3CA (n = 3). CDKN2A deletions were detected in 4 (44%) PDACs. In addition, 3 (33%) lost Smad4 expression. Interestingly, 7 (78%) PDACs arose in association with an IPMN and/or harbored a GNAS mutation. Conclusions: Lynch syndrome patients with PDAC frequently harbor germline MSH2 or MSH6 alterations. Although their tumors can be medullary, they are more often tubular in morphology and arise in association with an IPMN. As IPMNs are amenable to imaging, they represent ideal lesions for early detection strategies in these high-risk patients. Aatur Singhi, Siraj M Ali, Joel Greenbowe, Jeffrey S Ross, Khanh Nguyen, Marina Nikiforova, Herbert J Zeh, Inderpal S Sarkaria, Nathan Bahary. University of Pittsburgh Medical Center, Pittsburgh, PA; Foundation Medicine Inc, Cambridge, MA. Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers with a 5-year survival of 6%. Current therapeutic regimens are largely ineffective and underscore the need for novel treatment strategies. Chromosomal rearrangements involving the anaplastic lymphoma kinase (ALK) and various partner genes are considered drivers of tumorigenesis, and have been identified in several neoplasms. In addition, the ALK protein inhibitors crizotinib and ceritinib have proven efficacy in patients with ALK-rearranged tumors. Therefore, the ALK fusion protein represents an attractive target for directed therapy. As part of clinical care, we identified a PDAC harboring an EML4-ALK translocation, which prompted further evaluation of the prevalence and corresponding clinicopathologic features of ALK-rearranged PDACs. Design: Comprehensive genomic profiling was performed on 1616 PDACs in the course of clinical care that examined 236 genes and 19 genomic rearrangements. A separate cohort of 498 resected PDACs on tissue microarrays was evaluated by both an ALK break-apart probe and ALK immunohistochemistry. Results: Overall, 3 of 2114 PDACs harbored an exon 13 EML4-exon 20 ALK fusion gene. The patients consisted of 2 males and 1 female that ranged in age from 32 to 43 years. Morphologically, 2 cases were tubular-type PDACs and 1 was a colloid carcinoma. Of the 2 tubular-type PDACs, 1 showed prominent extracellular mucin. Besides the EML4-ALK fusion gene, other molecular abnormalities among the 3 tumors included a BAP1 mutation; STK11 mutation; and lastly, a TP53 mutation, CDKN2A/B deletion and MYC gene amplification. However, KRAS and SMAD4 alterations were absent in all 3 EML4-ALK-positive PDACs. Two cases developed distant organ metastases. One patient, who also harbored a BAP1 mutation, was treated with crizotinib, but developed neutropenia. Upon switching to ceritinib, a reduction in serum CA19-9 from 315 to 23.5 units/mL (normal limits) and radiographic response within 2 months was observed. However, within 7 months, the patient developed resistance. Repeat molecular testing of a newly developed lung metastasis lacked the BAP1 mutation, but now harbored a PBRM1 mutation.
Clinicopathologic and Molecular Analysis of Pancreatic Ductal Adenocarcinoma in Patients with Lynch Syndrome
A Clinicopathologic Study of ALK Rearrangements in Pancreatic Ductal Adenocarcinoma
Conclusions:
The frequency of ALK rearrangements in PDAC was 0.14%. EML4-ALK-positive PDACs were characterized by a young age, abundant extracellular mucin and absence of KRAS and SMAD4 mutations. While ALK-rearranged PDACs were responsive to ALK inhibitors, resistance did develop over time. . Nine patients were excluded due to lack of follow up. Cytology diagnostic categories atypical, suspicious and malignant were considered positive; insufficient and negative-negative Results: Male:female ratio was 1:1, age range 6-98 years and the median age 68years. 629 patients had a single BD/EUS FNAP, 136 patients had 2-7 procedures. The cytology diagnoses were insufficient 56 (7.2%), negative 301 (38.8%), atypical 99 (12.8%), suspicious 91 (11.7%) and malignant 227 (29.3%). Neoplasia was confirmed in 497 patients (398 true positive, 99 false negative). 267 patients were benign (238 true negatives, 29 false positives). The sensitivity of cytological diagnosis was 80%, specificity 89.1%, diagnostic accuracy 83.2%, positive predictive value (PPV) 93.2% and negative predictive value (NPV) 70.6%. Specific cytological diagnoses of tumour included pancreato-biliary/metastatic/hepatocellular carcinoma, neuroendocrine tumour/carcinoma, lymphoma, solid pseudopapillary tumour and mucinous neoplasm. Chronic pancreatitis was not diagnosed on cytology. Histology was available in 29/56 (51.7%) insufficient, 85/301 (28.3%) negative, 51/99 (51.5%) atypical, 40/91 (43.9%) suspicious and 50/226 (22.1%) malignant; the proportion of malignancy being 12/29 41.3% insufficient (NPV 65.7), 37/85 43.5% negative( NPV 71.2), 30/51 58.8% atypical (PPV 77), 37/40 suspicious (PPV 92), 50/50 100% malignant (PPV 99.5) cytological categories. EUS FNAP had diagnostic accuracy of 84%, sensitivity 80.7%, specificity 90%, PPV 93% and NPV 72.2%. Clinical/radiological evidence of disease progression over 4-144 weeks confirmed malignancy in 22/136 (16.2%) patients with multiple inconclusive BD/EUS FNAP. Conclusions: Combined BD and EUS FNA pancreas has a high diagnostic accuracy in pancreato-biliary malignancy. Surgical intervention for diagnosis is most useful in management of cytological categories insufficient, atypical or suspicious with proportionately increasing detection of malignancy.
GATA-3 Expression in Pancreas Cancer
Sagar J Vishal, Craig Dunseth, James J Mezhir, Andrew M Bellizzi. University of Iowa, Iowa City, IA. Background: GATA-3 is a transcription factor critical to Th2 cell, breast ductal epithelial, and urothelial differentiation, and immunohistochemistry (IHC) for this protein has emerged as a key diagnostic adjunct in support of breast or urothelial origin. Expression in tumors from these sites tends to be diffuse/strong. Recently, one group reported GATA-3 expression in up to 40% of a small number of pancreas cancers, challenging the value of this marker. We performed a detailed expression analysis in large cohort of pancreatic adenocarcinomas (PDAs), using the two dominant, commercially available GATA-3 clones. Design: Tissue microarrays were constructed from 248 primary and 97 metastatic PDAs (tumors arrayed in triplicate). Most of the metastatic cases involve regional lymph nodes excised at the time of Whipple and thus are matched to primaries. GATA-3 IHC was performed with the L50-823 and HG3-31 clones. Cases were score for extent (%) and intensity (0, 1+, 2+, 3+) of staining and an H-score (extent*intensity) calculated. Fisher's exact, Mann-Whitney, and Wilcoxon matched pairs tests were performed, as appropriate, with p<0.05 considered significant. Results: Overall, GATA-3 immunopositivity was seen in 24% (81/331) and 11% (36/332) of tumors with the L50-823 and HG3-31 clones, respectively (p<0.0001).
Expression tended to be weak and patchy, with mean and median H-scores for the various combinations of clone and primary vs metastatic status ranging from 8-44 and 1-8, respectively. L50-823-positivity appears stronger than HG3-31-positivity in primaries (p=0.06) but not metastases (p=0.4). In matched primary-metastatic pairs, GATA-3 positivity was stronger in metastases with both the L50-823 (p=0.0002) and HG3-31 (p=0.049) clones. Detailed expression data are presented in the Table. L50 Conclusions: Although GATA-3 immunopositivity is not uncommon in PDA, it was not as common as reported in one recent study, which utilized the L50-823 clone. As opposed to typical expression in breast and urothelial cancer, which in our experience produces H-scores in the 150-300 range, expression in PDA is weak and patchy. Attention to strength of positivity should prevent diagnostic confusion. We plan to investigate the specificity of this "low-level" GATA-3 positivity, by examining GATA-3 in a large series of upper GI and lung adenocarcinomas, which tend to be differential considerations in ("CK7-positive-only") metastases of unknown primary. Results: After a mean follow-up of 20 months (range, 2-69 months), the median OS was 21 months and the 3-year OS was 35.7 %. In multivariate analysis, highly-dense stroma was an independent prognostic parameter for OS (p=0.001), PFS (p=0.007), LPFS (p=0.001) and DMFS (p=0.002), while αSMA expression lacked significance. Interestingly, highly-dense stroma retained significance for the four clinical endpoints only in early (pT1-2) but not late (pT3-4) stage tumors. Additionally, late pT-stage (pT3-4), the presence of lymph node metastases (pN+ vs pN0), perineural/neural invasion PNI and administration of adjuvant chemotherapy also correlated with prognosis in multivariate analysis. Altogether, stroma density constitutes an independent prognostic marker in PDAC patients treated with adjuvant chemotherapy. Conclusions: Our findings highlight the dynamic complexity of desmoplasia and indicate that highly-dense stroma can prevent tumor progression. Further validation of the prognostic value of stroma as a biomarker and its role in in PDAC patients after adjuvant chemotherapy is warranted and will be performed in a prospective study. Background: Grading and prognosis of pancreatic neuroendocrine tumors currently relies on mitoses and Ki67 proliferation rate. There has been increased interest in additional immunohistochemical markers that may provide independent prognostic information, such as O 6 -Methylguanine-DNA methyltransferase (MGMT), because it can potentially guide the use of alkylating chemotherapy agents. Prior studies have shown conflicting results as to whether loss of MGMT expression confers worse outcome. Design: Pancreatic neuroendocrine tumors were identified from the pathology database of a large academic medical center (1996 to 2013) and compiled in a tissue microarray. H&E and Ki-67 stained sections were used to classify the lesions as well-differentiated neuroendocrine tumors, WHO grades 1 and 2 (WDNET), versus poorly-differentiated neuroendocrine carcinoma, WHO grade 3 (PDNEC). Immunohistochemistry for synaptophysin, chromogranin, and MGMT were performed on each tumor. MGMT protein expression was scored if an internal positive control was present. Loss of MGMT was scored if less than 1% nuclear staining was present in tumor cells. Kaplan-Meier analysis was used to calculate overall survival (OS). Cox proportional hazards models were used to assess significance of MGMT with survival. Results: 170 primary pancreatic neuroendocrine neoplasmswere identified. Median age was 56 years, 93 (55%) were male, 162 (95%) were WDNETs, 8 (5%) were PDNECs. All cases were synaptophysin positive. The 5-year OS rate for the entire cohort was 78.5%. Loss of MGMT expression was seen in 67 tumors (39%). A univariate Cox regression analysis demonstrated that Grade 3 was associated with an increased hazard of death with a likelihood ratio of 21.9 (p<0.0001). Loss of MGMT expression has no significant effect on survival (p=0.28).
Genetic and Epigenetic Changes in Stromal Cells
Conclusions:
Overall, patients were predominantly young and had WDNETs. As expected, PDNEC had worse OS compared to WDNET. In a Cox regression analysis, the factor associated with increased hazard of death was PDNEC. Loss of MGMT immunohistochemical expression is not an independent predictor for worse survival. Design: First, we compared the pathological changes among chronic pancreatitis (CP) tissues, PDAC, and adjacent non-neoplastic pancreatic tissues (ANPTs). Second, we detected the profile of MDSC subsets in patients with PDAC by immunofluorescence double staining and flow cytometry. Third, we investigated the characteristics of two novel MDSC subsets including the phenotype, morphology, gene expressions and immune-suppressive function. Finally, we studied the relationship between these two novel MDSC subsets and tumor progression. Results: We found that lymphocytic perineural cuffs were frequently identified in chronic pancreatitis (CP) tissues and adjacent non-neoplastic pancreatic tissues (ANPTs), but not in PDAC with perineural invasion. Background: Adenocarcinomas from gastrointestinal (GI) tract and pancreatobiliary tree frequently share morphologic features. Several markers of pancreatobiliary differentiation have been described in the literature to help the differentiation; however, none have high specificity and sensitivity. T-complex-associated-testis-expressed 3 (TCTE3) encodes a dynein light chain in cilia and flagella in sperm. Here we introduce it as a novel pancreatobiliary marker and propose its diagnostic utility. Design: A large panel of 224 adenocarcinomas from 10 different locations in the GI tract were studied, including GE junction (20), stomach (30), ampulla (16), pancreas (36), extrahepatic common bile duct (CBD), and gallbladder (15), cholangiocarcinoma (19), hepatocellular carcinoma (HCC) (20), small intestine other than ampulla (12), colon (32), and rectum (24). Tissue microarrays were constructed and tumors stained using a TCTE3 antibody (Sigma-Aldrich). Positivity was defined as ≥ 5% tumor cells with unequivocal cell membrane/cytoplasmic staining. Histopathological data were correlated with the staining and analyzed by Chi-square test (JMP 11.0) . Results: TCTE3 expression was characterized by a strong , well defined cell membrane/ cytoplasmic pattern in the normal pancreatobiliary epithelium, including large and small bile ducts/ductules in liver and pancreas and epithelium of gallbladder. It was not expressed in normal esophageal and gastric mucosa, hepatocytes, pancreatic acini and islets, small and large intestinal epithelium, or any non-epithelial cells. Positive TCTE3 stain was found in 86% of pancreatic duct adenocarcinomas, 47% of cholangiocarcinomas, 56% of ampullary adenocarcinoma, 27% of CBD/gallbladder adenocarcinomas, and 35% of GEJ adenocarcinomas. Only 3% of gastric and 6% of colon cancers exhibited positive staining. No expression was found in all the small intestinal (other than ampulla) cancers, rectal cancers, and HCCs. The staining positivity was not associated with grades or subtypes (for ampullary and cholangiocarcinoma). TCTE3's sensitivity and specificity for the diagnosis of pancreatic cancer in this current series was 86% and 83%.
The results demonstrate that TCTE3 may have diagnostic utility for pancreatic ductal carcinoma and in the separation of gastric cancer and small intestinal cancer from tumors of the pancreatobiliary tree. Correlation with intestinal marker and more investigation of non-GI tract tumors are needed to further strengthen the utility of TCTE3 as a specific pancreatobiliary marker.
